- |||||||||| Revlimid (lenalidomide) / BMS, Darzalex IV (daratumumab) / J&J
[VIRTUAL] Ex vivo expanded NK cells exhibit potent cytotoxicity against multiple myeloma. () - May 30, 2021 - Abstract #EACR2021EACR_2163;
We aimed to investigate whether our GTA002 NK cell product, expanded and differentiated ex vivo from cord-blood derived CD34+ hematopoietic stem cells, will in vitro effectively kill target various MM cell lines...Representative model MM cell lines were chosen based on their sensitivity/resistance to lenalidomide, bortezomib (BTZ) and CD38 surface expression, latter associated with responsiveness to daratumumab treatment: MM.1S, LP1, NCI-H292, OPM2, RPMI-8226, U266B1, KMS11 and KMS11/BTZ...Receptor and ligand expression of effector and target cells, respectively, will be determined by flow cytometry Results and Discussions We observed cytotoxicity of GT002 at E:T ratio 10:1 in all model MM cell lines irrespective of their chemoresistance status or CD38 surface antigen density...More importantly, we observed high killing efficiency also in U266B1 cells with low CD38 expression, which is indicative of the refractoriness to daratumumab therapy. Conclusion Our experimental data show proof of efficient cytotoxic capacity of ex vivo expanded NK cells against MM in vitro, and a strong indication that they can provide a novel source of cellular immunotherapy used to treat MM patient target groups with unmet medical needs, including those with relapsed refractory disease.
- |||||||||| Revlimid (lenalidomide) / BMS, Darzalex IV (daratumumab) / J&J
[VIRTUAL] Ex vivo expanded NK cells exhibit potent cytotoxicity against multiple myeloma. () - May 30, 2021 - Abstract #EACR2021EACR_2162;
We aimed to investigate whether our GTA002 NK cell product, expanded and differentiated ex vivo from cord-blood derived CD34+ hematopoietic stem cells, will in vitro effectively kill target various MM cell lines...Representative model MM cell lines were chosen based on their sensitivity/resistance to lenalidomide, bortezomib (BTZ) and CD38 surface expression, latter associated with responsiveness to daratumumab treatment: MM.1S, LP1, NCI-H292, OPM2, RPMI-8226, U266B1, KMS11 and KMS11/BTZ...Receptor and ligand expression of effector and target cells, respectively, will be determined by flow cytometry Results and Discussions We observed cytotoxicity of GT002 at E:T ratio 10:1 in all model MM cell lines irrespective of their chemoresistance status or CD38 surface antigen density...More importantly, we observed high killing efficiency also in U266B1 cells with low CD38 expression, which is indicative of the refractoriness to daratumumab therapy. Conclusion Our experimental data show proof of efficient cytotoxic capacity of ex vivo expanded NK cells against MM in vitro, and a strong indication that they can provide a novel source of cellular immunotherapy used to treat MM patient target groups with unmet medical needs, including those with relapsed refractory disease.
- |||||||||| Revlimid (lenalidomide) / BMS, Darzalex IV (daratumumab) / J&J
[VIRTUAL] Ex vivo expanded NK cells exhibit potent cytotoxicity against multiple myeloma. () - May 30, 2021 - Abstract #EACR2021EACR_2161;
We aimed to investigate whether our GTA002 NK cell product, expanded and differentiated ex vivo from cord-blood derived CD34+ hematopoietic stem cells, will in vitro effectively kill target various MM cell lines...Representative model MM cell lines were chosen based on their sensitivity/resistance to lenalidomide, bortezomib (BTZ) and CD38 surface expression, latter associated with responsiveness to daratumumab treatment: MM.1S, LP1, NCI-H292, OPM2, RPMI-8226, U266B1, KMS11 and KMS11/BTZ...Receptor and ligand expression of effector and target cells, respectively, will be determined by flow cytometry Results and Discussions We observed cytotoxicity of GT002 at E:T ratio 10:1 in all model MM cell lines irrespective of their chemoresistance status or CD38 surface antigen density...More importantly, we observed high killing efficiency also in U266B1 cells with low CD38 expression, which is indicative of the refractoriness to daratumumab therapy. Conclusion Our experimental data show proof of efficient cytotoxic capacity of ex vivo expanded NK cells against MM in vitro, and a strong indication that they can provide a novel source of cellular immunotherapy used to treat MM patient target groups with unmet medical needs, including those with relapsed refractory disease.
- |||||||||| Revlimid (lenalidomide) / BMS, Darzalex IV (daratumumab) / J&J
[VIRTUAL] Ex vivo expanded NK cells exhibit potent cytotoxicity against multiple myeloma. () - May 30, 2021 - Abstract #EACR2021EACR_2160;
We aimed to investigate whether our GTA002 NK cell product, expanded and differentiated ex vivo from cord-blood derived CD34+ hematopoietic stem cells, will in vitro effectively kill target various MM cell lines...Representative model MM cell lines were chosen based on their sensitivity/resistance to lenalidomide, bortezomib (BTZ) and CD38 surface expression, latter associated with responsiveness to daratumumab treatment: MM.1S, LP1, NCI-H292, OPM2, RPMI-8226, U266B1, KMS11 and KMS11/BTZ...Receptor and ligand expression of effector and target cells, respectively, will be determined by flow cytometry Results and Discussions We observed cytotoxicity of GT002 at E:T ratio 10:1 in all model MM cell lines irrespective of their chemoresistance status or CD38 surface antigen density...More importantly, we observed high killing efficiency also in U266B1 cells with low CD38 expression, which is indicative of the refractoriness to daratumumab therapy. Conclusion Our experimental data show proof of efficient cytotoxic capacity of ex vivo expanded NK cells against MM in vitro, and a strong indication that they can provide a novel source of cellular immunotherapy used to treat MM patient target groups with unmet medical needs, including those with relapsed refractory disease.
- |||||||||| GT-002 / Gabather
Trial completion: GAB-001: Study of Ascending Single Oral Dose of GT-002 in Healthy Volunteers (clinicaltrials.gov) - Feb 5, 2020
P1, N=32, Completed,
Conclusion Our experimental data show proof of efficient cytotoxic capacity of ex vivo expanded NK cells against MM in vitro, and a strong indication that they can provide a novel source of cellular immunotherapy used to treat MM patient target groups with unmet medical needs, including those with relapsed refractory disease. Recruiting --> Completed
|
